clinical trial · NCT03727139
Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"
Takeda·—·completed·n = 1,021
Parkinson's DiseaseRasagiline
brief summary
The purpose of this survey is to evaluate the long-term safety of Rasagiline (AZILECT) in patients with Parkinson's disease in daily clinical practice and also collect efficacy information.
started
Nov 1, 2018
primary completion
Oct 31, 2021
completion
Oct 31, 2021
last updated
Mar 8, 2024
detailed description
The drug being tested in this survey is called rasagiline tablet. This tablet is being tested to treat people with Parkinson's disease.
This survey is an observational (non-interventional) study and will look at the long-term safety and efficacy of the rasagiline tablet in the routine clinical setting. The planned number of observed patients will be approximately 1000.
This multi-center observational trial will be conducted in Japan.
official title
AZILECT Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol